Neuralink raises $600M at $9B valuation, advancing brain-computer interface tech.

Neuralink raises $600M at $9B valuation, advancing brain-computer interface tech.

Elon Musk's brain-computer interface (BCI) startup, Neuralink, has secured a $650 million funding round, bringing its pre-money valuation to approximately $9 billion [1]. The Series E round, announced on Monday, included notable investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital [1].

Neuralink's latest funding round follows a $280 million Series D raise in 2023, with an additional $43 million tranche added later that year. The company has made significant progress since then, conducting human clinical trials and receiving a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its brain chip technology [1]. This designation aims to expedite the development and regulatory review of experimental medical technologies.

The funding will support Neuralink's hardware development program, including the expansion of its clinical trials and the hiring of additional engineers to accelerate research efforts. The company plans to expand patient access to its technology, potentially launching more trials or expanding existing ones [3].

Neuralink's brain chip technology, known as the N1, is designed to enable individuals with quadriplegia to control computers using their thoughts. The device, about the size of a coin, is implanted using a custom surgical robot called the R1. The N1 has been used in five patients and is part of the FDA's Breakthrough Devices Program [3].

The BCI market is rapidly evolving, with several companies developing similar technologies. Competitors such as Synchron Inc., backed by Jeff Bezos' Bezos Expeditions fund, have also made strides in BCI technology. Synchron's implant, which is less invasive, is currently used by 10 patients and is being integrated with Nvidia's AI software to reduce latency [3].

The advancements in BCI technology have vast potential applications, including mental health therapy, assistive communication for individuals with speech impairments, cognitive enhancement, and disease detection [2]. The integration of AI in BCI devices is also expected to significantly improve data interpretation and real-time interaction.

As Neuralink continues to advance its technology, it is likely to attract further investment and attention from the medical and technology communities. The company's focus on expanding clinical trials and patient access indicates a commitment to making its technology more widely available.

References:
[1] https://techcrunch.com/2025/06/02/elon-musks-neuralink-closes-a-650m-series-e/
[2] https://ambiq.ai/community/understanding-brain-health-through-brain-computer-interface-technology/
[3] https://siliconangle.com/2025/06/02/neuralink-raises-another-650m-reported-9b-pre-money-valuation/